Loading stock data…
Tango Therapeutics (TNGX)
N/A
Market Closed
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
Historical Price
No chart data available for TNGX
Whystock Brain
The Narrative
Tango Therapeutics, Inc. in the Healthcare sector is trading at $32.56 with a market capitalization of $5.3B. Wall Street consensus targets $43.45 (11 analysts), implying a +33.5% move over the next 12 months. The stock is currently near its 52-week high of $34.39, remaining 116.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +33.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $53.81M↑ | $3.18M↓ | $5.39M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$48.77M↓ | -$41.86M↓ | $14.07M↑ | -$40.97M↑ | -$42.53M |
| Net Income | -$45.51M↓ | -$38.75M↓ | $15.88M↑ | -$38.85M↑ | -$39.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.31B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.39%
Volume
Today's trading volume
-
Recent News
This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In.
XBI has “moved higher a record 12 of 13 months,” Mizuho healthcare sector specialist Jared Holz wrote Friday.
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD
Revolution Medicines recently reported detailed Phase 3 RASolute 302 data showing once-daily oral daraxonrasib delivered unprecedented overall and progression-free survival benefits versus standard chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma, with all primary and key secondary endpoints met and a manageable safety profile. Because daraxonrasib improved survival in patients regardless of whether a tumor RAS mutation was identified and is being advanced in...
Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates
By Karen Roman Imviva Biotech said it is presenting two findings associated with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at the European Hematology Association 2026 Congress taking place on June 11-14, 2026, in Stockholm, Sweden. The global TENACITY-01 study had an 85.7% overall response rate, with a complete remission rate of 71.4% in adults […] The post Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates appeared first on ExecEdge.
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year
Wondering if Tango Therapeutics at around US$31.56 is priced too high, too low, or somewhere in between? This article walks through what the current share price might be implying about the stock's value. The stock has shown sharp moves recently, with returns of 46.8% over the last week, 37.1% over the last month, 253.4% year to date, and a very large gain of around 7x over the past year. Recent headlines around Tango Therapeutics have focused on its role in the biotech sector and how...
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.